Choose Your Cannabis Method
Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026)) — All Methods⚠️ Caution
🔵 Moderate
🔵 Moderate
🔵 Moderate
🔵 Moderate
About Retatrutide: The GLP-1 Gastric Slowing Effect
Why Method MattersAs a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide is expected to produce gastric slowing at least equivalent to — and potentially exceeding — tirzepatide (dual agonist) and semaglutide (single agonist). Oral cannabis absorption delays are predicted to apply on mechanistic grounds, though clinical pharmacokinetic data in retatrutide patients is not yet available.
| Method | Affected by GLP-1? | Onset on Retatrutide | Primary Risk |
|---|---|---|---|
| Edibles | Yes — significantly delayed | 2–4+ hours | ⚠️ Caution |
| Smoking | No — lung absorption | 1–10 min (unchanged) | 🔵 Moderate |
| Vaping | No — lung absorption | 1–10 min (unchanged) | 🔵 Moderate |
| Tinctures | Partial — depends on technique | Mixed (15 min–4+ hours) | 🔵 Moderate |
| CBD Oil | Yes — oral absorption delayed | 2–4+ hours | 🔵 Moderate |
Check Your Full Medication List
Taking Retatrutide plus other medications? Use InteractSafe to review your complete combination.
Retatrutide + Cannabis Full Profile →Or open the full interaction checker · Free · No account required